The company's lead investigational drug candidate, CM-101, is targeting the chemokine CCL24, an important driver of fibrotic processes.
This Phase 1b clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in people with nonalcoholic fatty liver disease.
Patients will be randomised to receive doses of CM-101 or placebo for 12 weeks followed by a recovery phase.
ChemomAb is a clinical-stage biopharmaceutical company that specializes in the development of proprietary monoclonal antibodies directed towards novel targets for the treatment of fibrotic-inflammatory disorders including NASH as well as orphan indications.
The antibodies are designed to treat patients with fibrotic and inflammatory diseases through a novel dual mechanism of action that interferes with fibrosis processes directly as well as attenuates the inflammatory process that supports the fibrotic milieu and disease progression.
The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval